---
title: "China National Pharmaceutical Group plans to uniformly register and issue RMB 30 billion non-financial corporate debt financing instruments within China"
description: "China National Pharmaceutical Group Corporation plans to register and issue RMB 30 billion non-financial corporate debt financing instruments in China. The funds raised will be used to repay loans, bo"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/203023085.md"
published_at: "2024-04-29T00:13:03.000Z"
---

# China National Pharmaceutical Group plans to uniformly register and issue RMB 30 billion non-financial corporate debt financing instruments within China

> China National Pharmaceutical Group Corporation plans to register and issue RMB 30 billion non-financial corporate debt financing instruments in China. The funds raised will be used to repay loans, bonds, supplement working capital, reserve funds, and project construction

According to the news from Zhitong Finance and Economics APP, China National Pharmaceutical Group Corporation (01099) announced that, in order to meet the actual needs of supplementing operating and reserve funds, ensuring smooth direct financing channels, reducing financing costs, and improving debt structure, on April 26, 2024, the board of directors proposed to register and issue a quota of Non-Financial Corporate Debt Financing Instruments (TDFI) within China.

The registered amount is a quota of RMB 30 billion for non-financial corporate debt financing instruments, including: RMB 25 billion for short-term varieties (within one year) and RMB 5 billion for medium to long-term varieties (generally not exceeding 10 years). The raised funds will be used for purposes including but not limited to repaying financial institution loans, credit-related matured bonds, supplementing operating and reserve funds, as well as other purposes in compliance with relevant laws and regulations. The funds raised from medium to long-term varieties can also be used for project construction

### Related Stocks

- [01099.HK - SINOPHARM](https://longbridge.com/en/quote/01099.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 渣打 CFO 閃辭跳槽打擊大 股價續跌 分析︰過去為集團帶來倍數升幅「曾產生變革性影響 」 | 渣打銀行（2888）CFO 杜智高（Diego De Giorgi）突然離任，轉任阿波羅全球管理的歐洲、中東及非洲地區主管。此消息導致渣打股價大幅下跌，昨日收市跌 1.9%，今日再跌 0.9%。高盛分析認為此人事變動令人意外，可能影響 CE | [Link](https://longbridge.com/en/news/275577029.md) |
| 閲文 (772) 發盈警，新麗傳媒再 18 億商譽減損 | 閲文集團發布盈警，因新麗傳媒 18 億元商譽減損，預計 2025 年虧損 7.5 億至 8.5 億元。新麗傳媒利潤減少，扣除非經常性利潤將降至 8 至 9 億元。面對觀眾對高品質內容的期待，新麗傳媒將調整生產策略，控制創作節奏，提升內容品質 | [Link](https://longbridge.com/en/news/275543341.md) |
| SoFi 與 OSL 集團 (863) 達戰略合作，引入數字資產交易服務，業務首次擴張至美國本土以外市場 | SoFi Securities（香港）有限公司與 OSL 集團達成戰略合作，首次將數字資產交易服務擴展至美國以外市場。此合作為香港投資者提供通過 SoFi Hong Kong 應用程式交易多種數字資產的機會，標誌著 SoFi 全球業務的重要 | [Link](https://longbridge.com/en/news/275689746.md) |
| 周大福 (1929) 內地門店據報春節後調高金飾售價最多 30% | 周大福計劃於春節後調高金飾售價，漲幅預計在 15% 至 30% 之間。部分門店已接獲通知，具體調價細節待實際更換價格標籤確認。調價原因是受國際及國內市場因素影響，黃金及原材料價格持續上漲。集團要求各部門及門店提前做好價格管理工作，以確保調價 | [Link](https://longbridge.com/en/news/275546562.md) |
| 微信支付「WeChat Pay 收錢碼」升級一年錄接近百萬宗交易，內地旅客佔 6 成，在港推「心水小店計劃」 | 騰訊旗下的微信支付在過去一年內升級的「WeChat Pay 收錢碼」已錄得近百萬宗交易，其中內地旅客佔比接近 60%。此外，微信支付在香港推出「心水小店計劃」，通過零費率及雙幣收款工具，幫助本地中小微餐飲商户把握節日商機，提升運營效率並擴大 | [Link](https://longbridge.com/en/news/275690270.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.